62 results about "Serum uric acid" patented technology

The invention disclosed the application of celery seed coumarins and flavanoid in preparing arthrifuge, anti-inflammatory agent or health food, which belongs to the natural occurring drugs and medical technology domain. The coumarins and flavanoid is the extract from acetic ether. The preparing method includes the following steps: selecting 10kg celery dry seed, adding 15-20 times of 75-95%(V / V) as the seed or extracting with 4-5 times of 75-95%(V / V) alcohol at higher temperature, heating for 1-1.5h every time; vacuum condensing the extracts until nearly all the alcohol is away; adding 1-2 times of water, extracting with 1 / 3 volume of the diluted solution sherwood oil (60-90DEG C) for 2-3 times; reclaiming the sherwood oil; extracting the water layer with 1 / 3 volume of acetic ether for 4 times; reclaiming the acetic ether to get the extracts. The invention has very simple preparing technologies; the product in the invention has obvious anti-inflammatory function; it can also decrease the amount of serum uric acid of rats.

The invention relates to application of celery seed extract to preparation of medicine or health-care food for resisting to hyperuricemia and gout and further provides medicine or health-care food for treating hyperuricemia and gout. Celery seed extract serves as the active constituent, and an appropriate number of medical carriers or auxiliary constituents are added, so that a preparation is obtained. The medicine for health-care food is simple in preparation process, the celery seed extract can obviously lower serum uric acid of model mice suffering from hyperuricemia caused by oteracil potassium salt, lower the activity of xanthine oxidase to different degrees, achieve an obvious inhibition effect on arthritis of the mice, prevent and treat hyperuricemia or gout and be applied to preparation of the medicine or health-care food for resisting to hyperuricemia and gout.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

Provided is an enteric preparation for preventing and curing hyperuricemia and gout. The employing essential component of the preparation is enteric capsules of uricase. The causes of the hyperuricemia and the gout are that uric acid is over generated and / or the uric acid is diminished in discharging, and metabolic diseases increasing the density of serum uric acid. About one third of the uric acid of the human body is defecated from intestinal canals, and the uric acid entering the canals still can be reabsorbed. When the hyperuricemia and the gout happen, the proportion of the uric acid defecated from the intestinal canals is increased. The uricase is capable of rapidly effectively dissociating the uric acid. The uricase of the enteric preparation after being orally taken is disintegrated in the intestinal canals and is diffused from blood into the uric acid of the intestinal canals, preventing the uric acid from reabsorbing, thereby reducing the density of the serum uric acid, achieving the purposes of preventing and curing the hyperuricemia and the gout. The oral uricase has the characteristics of non-absorbent property by the intestinal canals, keeping out of blood circulation, no producing of antibodies of organisms and allergic response, providing a new method for preventing and curing the hyperuricemia and the gout.

The invention belongs to the field of medicines and discloses a mango leaf extract and application thereof. Mango leaves are subjected to refluxing extraction and concentration via aliphatic alcohol with 1-4 carbon atoms, and the obtained product is extracted and purified via low-polarity organic solvent and is refined to obtain the mango leaf extract. The mango leaf extract disclosed by the invention contains mangiferin and homomangiferin which are at specific proportion, and is better than a mangiferin monomer in the solubility. Pharmacological research proves that the mango leaf extract has the effects of lowering the level of serum uric acid of a hyperuricemia mice and reducing blood sugar, and is better than the mangiferin. Therefore, the invention provides application of the mango leaf extract provided by the invention to the medicine for preventing or treating the metabolic syndrome.

The invention relates to an application of Graveobioside A in the preparation of drugs or healthcare food for preventing hyperuricemia and gout. The invention also provides a drug or healthcare food for treating hyperuricemia and gout. Graveobioside A is the active component and is mixed with a proper amount of pharmaceutical carrier or excipient to prepare preparations. Graveobioside A can prominently reduce uric acid in serum of an oteracil potassium caused hyperuricemia model mouse, reduces the activity of xanthine oxidase at different levels, and prominently inhibit the arthritis of mouse. Graveobioside A can treat and prevent hyperuricemia and gout and can be used to prepare drugs or healthcare food for preventing hyperuricemia and gout.

The invention relates to a PEGylation urate oxidase compound as well as the preparation method thereof and the preparation of PEGylation urate oxidase compound as well as the application thereof, particularly relates to a PEGylation urate oxidase compound which has extremely low immunogenicity and anaphylaxis, can be applied repetitively and has a long acting as well as the preparation method thereof and the preparation of PEGylationurate oxidasee compound as well as the application thereof. The invention adopts a modification method which has high selectivity to a N-terminal of a urate oxidase, which means that PEG active ester is connected with the N-terminal of the urate oxidase by covalence bond, the uniformity of products is greatly improved, the products are easy to be purified, the activity of the purified products can be better preserved and the immunogenicity of prototype protein of the urate oxidase can be reduced obviously. The PEGylation urate oxidase compound can prevent systemic anaphylaxis when applied, can be applied repetitively and has the efficacy of treating and preventing gout, reducing the level of serum uric acid, preventing tumor lysis syndrome and improving the renal function.

The invention provides sunflower head extract prepared by a crystallization enzymolysis method and a preparation method of the sunflower head extract. A sunflower head is a pure natural traditional Chinese medicine or a material both used as medicine and food; the sunflower head is scientifically extracted to prepare a functional health product both used as medicine and food, which has the effects of resisting gout, treating hyperuricemia, improving the immunity, lowering blood glucose and blood lipid, protecting kidney and liver, eliminating swelling, resisting inflammation and relieving pain and has the effects of dissolving uric acid calculus, lowering serum uric acid concentration, eliminating swelling and resisting inflammation, adjusting purine and uric acid metabolism, balancing in-vivo acid-base equilibrium and balancing in-vivo hormones; the product is safe, has no side effect, has remarkable health effect and can be eaten for a long period, so that a market development prospect is very good.

Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

The invention discloses a method for detecting uric acid by using mesoporous organic silicon hollow nanosphere fixed uricase, and belongs to the technical field of uric acid detection. The experimenttakes monodispersed SiO2 nanospheres as a hard template, and adopts a one-step growth-induced corrosion method to prepare mesoporous organic silicon hollow nanospheres. The method is simple and easy to operate, is low in requirement and highly controllable in synthesis process, and can synthesize hollow-structured mesoporous organic silicon nanospheres with different functional groups by using different precursors. The synthesized mesoporous organic silicon hollow nanospheres have ordered pore channels and uniform pore diameters, and internally contain hollow cavities. The synthesized mesoporous organic silicon hollow nanosphere fixed uricase is used to detect serum uric acid, so that the method for detecting uric acid by using the mesoporous organic silicon hollow nanosphere fixed uricaseis established, and an application prospect in rapid detection of serum uric acid is achieved.

The invention discloses application of a gallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The gallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine. The formula (I) is as shown in the specification.

The invention discloses application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia and in particular relates to application of high mangiferin and aglycon thereof in preparation of a medicament for preventing and treating hyperuricemia as well as gout and lithangiuria brought by the hyperuricemia, and a medicine application way. The high mangiferin and aglycon thereof provided by the invention can be used for obviously reducing the concentration of serum uric acid in an animal for experiment and have the serum uric acid inhibition effect similar to that of a xanthine oxidase inhibition medicament allopurinol; and simultaneously, the high mangiferin and aglycon thereof provided by the invention can be used for obviously improving the concentration of uric acid in urine and have the uric acid excretion promoting function similar to that of a uric acid excretion promoting medicament probenecid. The high mangiferin and aglycon thereof provided by the invention are efficient, low in toxicity and high in safety, thus the high mangiferin and aglycon thereof are wide in application prospect.

The invention discloses application of Gynura procumbens to the production of medicine, healthcare food or functional food for preventing and treating hyperuricemia. Evidence is provided to show that the Gynura procumbens has an evident effect of preventing and treating the hyperuricemia, can lower the serum uric acid value of a patient with the hyperuricemia, has an evident uric acid lowering effect and is capable of relieving the clinical symptoms of the patient with the hyperuricemia.

The invention relates to a construction method for an acute hyperuricemia tree shrew model. The method comprises the following steps: (1) selecting adult healthy tree shrew with body weight of 110 to 150 g and an age of 1 to 3 years; (2) respectively measuring fasting serum uric acid values of males and females of tree shrew selected in the step (1); (3) carrying out conventional breeding on the tree shrew selected in the step (1) and pretreating the tree shrew by grasping and releasing the tree shrew with hand; and (4) injecting the tree shrew treated in the step (3) with an oteracil potassium suspension so as to obtain the acute hyperuricemia tree shrew model, wherein the amount of the used oteracil potassium suspension is 40 mg / kg to 100 mg / kg on the basis of the body weight of the tree shrew. The model has typical disease symptoms, a quantity index has statistical significance, and serum urea nitrogen and serum creatinine values and histopathological results prove that such a model making dosage range is safe and does not result in influence on the liver and the kidney.

The invention relates to an application of herba lysimachiae total flavonoids in preparation of a medicine for relieving hyperuricemia. The content of total flavonoids in the herba lysimachiae total flavonoids is more than 60%, and the herba lysimachiae total flavonoids contain 7.0wt% to 10.0wt% of kaempferol, 6.0wt% to 9.0wt% of quercetin, 5.0wt% to 9.0wt% of rutin, 7wt% to 10wt% of epicatechin and 7.0wt% to 10wt% of hesperidin. The herba lysimachiae total flavonoids are high in total flavonoid content and definite in ingredients, and also have the function of obviously lowering serum uric acid of a model rat with the hyperuricemia under the condition of the total flavonoids in a low dose, so that the herba lysimachiae total flavonoids are high in safety and are of a good medicine for lowering high uric acid and treating gout. In addition, the herba lysimachiae total flavonoids are simple in preparation process and are suitable for industrial production and applications.

The invention discloses application of a digallate derivative which has a formula (I) and a pharmaceutically acceptable salt thereof to preparation of a medicine for treating hyperuricemia. The digallate derivative has a strong effect of inhibiting xanthine oxidase in vitro, can be used for reducing the level of serum uric acid of a mouse with hyperuricemia significantly, is dose dependent and can be used for treating hyperuricemia and gout or gout complications caused by hyperuricemia as a potential xanthine oxidase inhibitor and a potential uric acid lowering medicine.

The invention discloses a uric acid-reducing peptide drink and a preparation method thereof. The drink contains the following ingredients: saury uric acid-reducing peptide dry powder, fruit juice, cane sugar, citric acid and a stabilizer, wherein the saury uric acid-reducing peptide dry powder is prepared by the following steps: mincing saury and then adding water, heating, adding protease to hydrolyze, then deactivating enzyme, centrifuging, removing upper-layer fish oil and lower-layer precipitates, taking a middle clear liquid, and carrying out spray-drying. According to the uric acid-reducing peptide drink and the preparation method thereof disclosed by the invention, a modern biological enzyme hydrolysis technology is adopted, and a uric acid-reducing ingredient in saury proteins is released and then prepared into the uric acid-reducing peptide drink product convenient to carry and drink through adding food auxiliary materials. The process disclosed by the invention is simple to operate, low in production cost and free from pollution; the obtained uric acid-reducing peptide drink product is high in uric acid-reducing effect and convenient to drink.

The invention provides a building method for an acute hyperuricemia animal model. The building method comprises the following steps: applying inosine to a rhesus monkey to obtain an acute hyperuricemia animal model. In the building method, the inosine is taken as an inducer for inducing rise of serum uric acid, and is applied to the rhesus monkey to build the hyperuricemia animal model for assessing the efficacy of decreasing serum uric acid. As proved by experiment results, the acute hyperuricemia animal model can be built by the method provided by the invention, and the model has high reproducibility; the hyperuricemia animal model built by the method can be used for evaluating the serum uric acid decreasing function of a PNP enzyme inhibitor, and is suitable for assessing the serum uric acid decreasing effect of an XO inhibitor. Moreover, the building method provided by the invention is simple, only injection of inosine into the rhesus monkey is required, and other medicaments are not required.

The invention relates to use of pterostilbene in preparing a medicine for preventing and treating high uric acid nephropathy, and belongs to the field of medicine, and provides use of the pterostilbene or a pharmaceutically acceptable salt thereof in preparing the medicine for treating and / or preventing the high uric acid nephropathy. Experimental results show that the pterostilbene can significantly reduce the level of serum uric acid, inhibits renal interstitial fibrosis, can significantly reduce the expression of fibrosis-related proteins such as alpha-SMA, collagenI, collagenIV and fibronectin, has a definite therapeutic effect on the high uric acid nephropathy, and provides a new option for clinical medication.

The invention discloses a traditional Chinese medicine composition which comprises the following components in parts by weight: 12-45 parts of astragalus, 12-45 parts of rhizoma anemarrhenae and 6-36 parts of the root bark of white mulberry. The composition disclosed by the invention is scientific in formula, achieves a synergistic effect among the components, has excellent effects of decreasing serum uric acid and reducing blood fat, can be used for effectively treating gout disease and hyperuricemia associated with hyperlipemia, does not have any toxic or side effect, can achieve the effect of improving the immunity of the organism and can be taken for a long time.

The invention provides an application of cassia ketoside in preparation of a xanthine oxidase inhibitor. In vitro tests prove that cassia ketoside has an obvious inhibitory effect on the activity of xanthine oxidase; a test by an experimental hyperuricemia mouse model proves that the cassia ketoside greatly reduces the level of serum uric acid in the model mouse; therefore, the cassia ketoside can be used for preparing the xanthine oxidase inhibitor and used for preparing products for inhibiting the activity of the xanthine oxidase to treat hyperuricemia.

The invention disclosed the application of celery seed coumarins and flavanoid in preparing arthrifuge, anti-inflammatory agent or health food, which belongs to the natural occurring drugs and medical technology domain. The coumarins and flavanoid is the extract from acetic ether. The preparing method includes the following steps: selecting 10kg celery dry seed, adding 15-20 times of 75-95%(V / V) as the seed or extracting with 4-5 times of 75-95%(V / V) alcohol at higher temperature, heating for 1-1.5h every time; vacuum condensing the extracts until nearly all the alcohol is away; adding 1-2 times of water, extracting with 1 / 3 volume of the diluted solution sherwood oil (60-90DEG C) for 2-3 times; reclaiming the sherwood oil; extracting the water layer with 1 / 3 volume of acetic ether for 4 times; reclaiming the acetic ether to get the extracts. The invention has very simple preparing technologies; the product in the invention has obvious anti-inflammatory function; it can also decrease the amount of serum uric acid of rats.

The invention relates to a PEGylation urate oxidase compound as well as the preparation method thereof and the preparation of PEGylation urate oxidase compound as well as the application thereof, particularly relates to a PEGylation urate oxidase compound which has extremely low immunogenicity and anaphylaxis, can be applied repetitively and has a long acting as well as the preparation method thereof and the preparation of PEGylationurate oxidasee compound as well as the application thereof. The invention adopts a modification method which has high selectivity to a N-terminal of a urate oxidase, which means that PEG active ester is connected with the N-terminal of the urate oxidase by covalence bond, the uniformity of products is greatly improved, the products are easy to be purified, theactivity of the purified products can be better preserved and the immunogenicity of prototype protein of the urate oxidase can be reduced obviously. The PEGylation urate oxidase compound can prevent systemic anaphylaxis when applied, can be applied repetitively and has the efficacy of treating and preventing gout, reducing the level of serum uric acid, preventing tumor lysis syndrome and improving the renal function.

The invention relates to suaeda salsa Pu'er green orange tea and a preparation method thereof. The suaeda salsa Pu'er green orange tea relates to tea. The suaeda salsa Pu'er green orange tea is prepared from the following components in parts by weight: 10-15 parts of suaeda salsa, 1-2 parts of germinated brown rice and 3-5 parts of green oranges. The invention discloses the suaeda salsa Pu'er green orange tea and the preparation method thereof. Made from suaeda salsa, Pu' er, small green oranges and germinated brown rice as raw materials, the tea has the function of reducing the serum uric acid concentration of human body, maintaining the serum uric acid of the human body in a normal range and reducing blood fat. In a preparation process, a tea leave press fit and tea cake cutting processis adopted, so that loose tea is prevented from filling directly, and the tea is convenient to transport and carry, and meanwhile, the taste and flavor of the tea leaves can be retained and enhanced.

The invention discloses a Chinese herbal medicine composition that clears heat and humidity, dispels wind and activates collaterals and the preparation method. The active ingredients of the invention are extracted from atractylodes, phellodendron bark, anemarrhena, cassia twig, honeysuckle stem, prepared rhizome of rehmanniae, gardenia, cassia twig, olibanum, clematis root, eupolyphaa sinensis, Chinese rhubarb, Oriental Waterplantain Rhizome, angelica, safflower and radix glycyrrhizae. The special medical active components in the invention have the functions of clearing heat and humidity, dispelling wind and activating collaterals. The medicine composition has obvious reducing function for serum uric acid abnormal rising caused by gout and has good pain easing and repercussion effects for various rheumatic complaints.

The invention belongs to the technical field of biology, and relates to a dendranthema indicum extract and application. A method for preparing the dendranthema indicum extract comprises the followingsteps: drying and smashing a dendranthema indicum raw material, adding ethanol, carrying out reflux extraction, carrying out solid-liquid separation after extracting, and collecting filtrate; removingthe ethanol in the filtrate through vacuum concentration, then sequentially adding petroleum ether and ethyl acetate for extracting, and concentrating an ethyl acetate layer into concrete, thus obtaining the dendranthema indicum extract. The dendranthema indicum extract disclosed by the invention has an obvious serum uric acid reducing function.

The invention discloses a traditional Chinese medicine formula for decreasing serum uric acid. The traditional Chinese medicine formula for decreasing the serum uric acid comprises the following medicinal materials in parts by weight: 25-35 parts of cornu bubali, 20-25 parts of adhesive rehmannia dried root, 10-15 parts of Chinese herbaceous peony, 10-15 parts of astragalus membranaceus, 8-13 parts of moutan bark, 10-14 parts of golden cypress, 10-15 parts of radix bupleuri, 10-15 parts of cape jasmine fruit, 10-15 parts of scutellaria baicalensis, 15-20 parts of grifola, 19-25 parts of orangepeel, 8-13 parts of ginger peel, and 30-45 parts of myotonin. According to the traditional Chinese medicine formula for decreasing the serum uric acid, cornu bubali, adhesive rehmannia dried root, radix paeoniae alba, moutan bark, astragalus membranaceus, radix bupleuri, golden cypress, scutellaria baicalensis, cape jasmine fruit, orange peel, grifola, myotonin and ginger peel are used as the rawmaterials and combined by ratio and then are processed into particles through certain processes; patients eating the formula are low in serum uric acid concentration; the recurrence rate is low; theformula is safe, and free from side effects.

The invention discloses a plant extract composition capable of regulating human uric acid and a preparation method thereof. In mass ratio, the plant extract comprises 35-45% of coconut milk powder, 11-21% of green papaya powder, 10-20% of carrot powder and 20-25% of tea polyphenol. The composition has the effect of remarkably reducing the uric acid. A bio-engineering technology is utilized to extract a variety of raw materials, so that the advantages of being high in extraction rate, free of toxic and side effects and environment-friendly are provided. The tea polyphenol is a natural antioxidant which has no toxic or side effect and no odor, consists of flavonol, anthocyanin, catechin, phenolic acid and depside; and the main component epigallocatechin gallate (EGCG) has the function of inhibiting xanthine oxidase and is suitable for the case of excessive production of uric acid.